- Home
- CNFR vs SNSE Comparison
CNFR vs SNSE Comparison
Compare CNFR & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- SNSE
- Stock Information
- Founded
- CNFR 2009
- SNSE 2005
- Country
- CNFR United States
- SNSE United States
- Employees
- CNFR N/A
- SNSE N/A
- Industry
- CNFR Property-Casualty Insurers
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- SNSE Health Care
- Exchange
- CNFR Nasdaq
- SNSE Nasdaq
- Market Cap
- CNFR 9.9M
- SNSE 10.5M
- IPO Year
- CNFR 2015
- SNSE 2021
- Fundamental
- Price
- CNFR $1.62
- SNSE $8.90
- Analyst Decision
- CNFR
- SNSE Strong Buy
- Analyst Count
- CNFR 0
- SNSE 4
- Target Price
- CNFR N/A
- SNSE $72.50
- AVG Volume (30 Days)
- CNFR 301.7K
- SNSE 8.3K
- Earning Date
- CNFR 11-12-2025
- SNSE 11-13-2025
- Dividend Yield
- CNFR N/A
- SNSE N/A
- EPS Growth
- CNFR N/A
- SNSE N/A
- EPS
- CNFR 2.45
- SNSE N/A
- Revenue
- CNFR $52,654,000.00
- SNSE N/A
- Revenue This Year
- CNFR $25.91
- SNSE N/A
- Revenue Next Year
- CNFR N/A
- SNSE N/A
- P/E Ratio
- CNFR $0.50
- SNSE N/A
- Revenue Growth
- CNFR N/A
- SNSE N/A
- 52 Week Low
- CNFR $0.42
- SNSE $5.00
- 52 Week High
- CNFR $1.33
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- CNFR 60.79
- SNSE 52.81
- Support Level
- CNFR N/A
- SNSE N/A
- Resistance Level
- CNFR $1.27
- SNSE $9.50
- Average True Range (ATR)
- CNFR 0.15
- SNSE 0.54
- MACD
- CNFR 0.03
- SNSE -0.25
- Stochastic Oscillator
- CNFR 67.87
- SNSE 93.68
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).